Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.67.

Several analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Alphatec in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Alphatec in a report on Tuesday, January 14th. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Finally, Piper Sandler upped their price objective on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th.

Insider Buying and Selling

In other news, CEO Patrick Miles sold 12,691 shares of Alphatec stock in a transaction on Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the sale, the chief executive officer now directly owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This trade represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David Sponsel sold 58,283 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the transaction, the executive vice president now owns 502,311 shares in the company, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 337,321 shares of company stock worth $3,828,060 over the last three months. 22.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Alphatec

Institutional investors have recently made changes to their positions in the company. Van ECK Associates Corp grew its stake in shares of Alphatec by 57.0% during the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after acquiring an additional 6,998 shares during the last quarter. Atria Investments Inc grew its stake in shares of Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after acquiring an additional 1,460 shares during the last quarter. Entropy Technologies LP grew its stake in shares of Alphatec by 14.9% during the third quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock worth $120,000 after acquiring an additional 2,800 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Alphatec during the third quarter worth about $431,000. Finally, Zions Bancorporation N.A. grew its stake in shares of Alphatec by 108.2% during the third quarter. Zions Bancorporation N.A. now owns 173,180 shares of the medical technology company’s stock worth $963,000 after acquiring an additional 89,992 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Trading Down 4.2 %

ATEC stock opened at $9.34 on Friday. Alphatec has a 1-year low of $4.88 and a 1-year high of $14.88. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -7.30 and a beta of 1.39. The business has a 50 day simple moving average of $10.95 and a two-hundred day simple moving average of $8.80.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Research analysts anticipate that Alphatec will post -1.08 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.